

Washington University School of Medicine

Digital Commons@Becker

Posters

2005: Alcoholism and Comorbidity

2005

Linkage signals for illicit drug phenotypes

Arpana Agrawal

Andrew C. Heath

Scott Saccone

Michele Pergadia

Danielle Dick

See next page for additional authors

Follow this and additional works at: <https://digitalcommons.wustl.edu/guzeposter2005>



Part of the [Medicine and Health Sciences Commons](#)

Recommended Citation

Agrawal, Arpana; Heath, Andrew C.; Saccone, Scott; Pergadia, Michele; Dick, Danielle; Grant, Julia; Ge, Su; Lynskey, Michael; Rice, John; Todorov, Alexandre; Todd, Richard; Goate, Alison; Wang, Jen; Shears, Shantia; Montgomery, Grant; Martin, Nicholas; and Madden, Pamela A., "Linkage signals for illicit drug phenotypes" (2005). *Posters*. Paper 4 Samuel B. Guze Symposium on Alcoholism. <https://digitalcommons.wustl.edu/guzeposter2005/4>

This Poster is brought to you for free and open access by the 2005: Alcoholism and Comorbidity at Digital Commons@Becker. It has been accepted for inclusion in Posters by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors

Arpana Agrawal, Andrew C. Heath, Scott Saccone, Michele Pergadia, Danielle Dick, Julia Grant, Su Ge, Michael Lynskey, John Rice, Alexandre Todorov, Richard Todd, Alison Goate, Jen Wang, Shantia Shears, Grant Montgomery, Nicholas Martin, and Pamela A. Madden

Linkage Signals for Illicit Drug Phenotypes



The Nicotine Addiction Genetics (NAG) Project

Arpana Agrawal, Andrew C. Heath, Scott Saccone, Michele Pergadia, Danielle Dick, Julia Grant, Su Ge, Michael Lynskey, John Rice, Alexandre Todorov, Richard Todd, Alison Goate, Jen Wang, Shantia Shears, Grant Montgomery, Nicholas Martin, and Pamela A. F. Madden

NICOTINE GENETICS CONSORTIUM

SENIOR INVESTIGATORS

Pamela Madden, Ph.D.

John Rice, Ph.D.

Andrew Heath, D.Phil.

Alison Goate, D.Phil.

Richard Todd, Ph.D., M.D.

Alexandre Todorov, Ph.D.

Washington University School of Medicine, USA

Nick Martin, Ph.D.

Queensland Institute of Medical Research, Australia

Jaakko Kaprio, M.D., Ph.D.

Leena Peltonen, M.D., Ph.D.

Markku Koskenvuo, M.D., Ph.D.

University of Helsinki, Finland

The Nicotine Addiction Genetics Project


(P.I: Dr. Pamela A.F. Madden)

- Families from the **Australian** twin registry
- **Proband is a heavy smoker** (20+ cigarettes/day and also includes 40+ cigarettes lifetime)
- Interviewee is affected twin or spouse from discordant pairs of ATR or spouse or random twin from concordant pairs
- Affected sibpair + additional affected sibs + both biological parents + unaffected sibs with nicotine exposure (fewer than 100 cigs lifetime)
- Estimated **400 families** with current tally of 200 families


Current data (Nfams=196)

- N = 196 families with **1036** individuals
- Average family size = **5**
- Founders = **395**
- Female = **541**
Male = **495**
- Mean age = **48 years**

Prevalence (%) of illicit drug abuse (DSM-IV) in NAG



Prevalence (%) of Illicit Drug Dependence (DSM-IV) in NAG




Phenotypic Definitions for Illicit Drugs


- **Mjsx** : Sum of marijuana dependence symptoms
- **Polyuse** : Sum of binary use variables (response to “have you ever used...”) for marijuana, cocaine, sedatives, stimulants, hallucinogens and opiates
- **Polydep4** : Sum of binary DSM-IV dependence for marijuana, cocaine, sedatives, stimulants, hallucinogens and opiates
- **Polyabu4** : Sum of binary DSM-IV abuse for marijuana, cocaine, sedatives, stimulants, hallucinogens and opiates
- **log(maxdrink)** : maximum drinks in a 24-hr period

All semi-continuous variables were **log-transformed**, gender, age and age² was regressed out and **residuals** were used for linkage analyses in **MERLIN-REGRESS** (without ascertainment correction).


Nicotine Addiction Genetics (NAG): Chromosome 1




Nicotine Addiction Genetics (NAG): Chromosome 3




Nicotine Addiction Genetics (NAG): Chromosome 4




Nicotine Addiction Genetics (NAG): Chromosome 6




Nicotine Addiction Genetics (NAG): Chromosome 8



Nicotine Addiction Genetics (NAG): Chromosome 10



Nicotine Addiction Genetics (NAG): Chromosome 13




Log (maximum alcohol drinks)

Is there an overlap with regions for illicit drugs?

Ref: Saccone, Heath, Madden (unpublished)

Nicotine Addiction Genetics (NAG): Chromosome 7



Linkage signals for Nicotine-related measures

Are there differences from the illicit drug linkage regions?

Ref: Madden & Heath (unpublished)

Position	Phenotype	LOD	P-value
Chr 2 : 84cM	FTND	1.81	.002
Chr 7 : 117cM	Max. Cigs	1.86	.002
Chr 13 : 105cM	FTND	1.71	.002
Chr 20 : 74cM	Max. Cigs	1.96	.001
Chr 22 : 57cM	FTND	2.01	.001

Conclusions

- The signals on chr 3, 4, 6, 8 and 10 seem to be **unique to illicit drug dependence**
- The signals from log(maxdrinks) overlaps with the finding from log (maxcigs)
- This signal on **chr 7** is well supported by other studies (e.g. COGA)
- The signal on **chr 6** maps fairly close to the **cannabinoid receptor** gene

Cannabinoid Receptor 1: Chromosome 6

Possible Candidate Gene ?

- CNR1 located chromosome 6@ **90cM**
- G-protein coupled receptor
- CB1 **K/O mice exhibit reduced mortality, hypoalgesia** but show some analgesic effects of THC (Zimmer et al, 1999, PNAS)
- Association study with 154 mood disordered patients and 165 control failed to show association between CB1 and psychotic symptoms
- Association study with 127 schizophrenic patients and 146 control failed to show association between CB1 and schizophrenia
- No association with alcohol-related phenotypes
- One study suggests that restricting AN and bingeing/purging AN may be associated with different alleles (14 vs 13 rep) of CNR1
- Long repeats correlated with ADHD in alcoholics in a Spanish sample

Work in Progress

- Aim 1: Refine illicit drug use, abuse & dependence **phenotypes** & combine with alcohol/nicotine
- Aim 2: Perform analyses on **full sample** of 400 families
- Aim 3: Calculation on **empirical p-values** from a 1,000 replicates of the data
- Aim 4: To include other **comorbid psychopathology**, such as conduct disorder, personality traits, depression